BIOCHEMICAL INVESTIGATION OF P-GLYCOPROTEIN
P-糖蛋白的生化研究
基本信息
- 批准号:2187790
- 负责人:
- 金额:$ 19.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-01-01 至 1996-12-31
- 项目状态:已结题
- 来源:
- 关键词:6 thioguanine 6 thiopurine CHO cells P glycoprotein adenosinetriphosphatase affinity labeling binding proteins biochemistry catalyst fluorescent dye /probe glycoprotein structure liposomes maleimides membrane transport proteins molecular site multidrug resistance nucleotide analog nucleotides phosphatase inhibitor protein purification protein reconstitution structural biology
项目摘要
Multidrug-resistance is a situation encountered in cancer patients in
which the tumor becomes resistant to a variety of cytotoxic anti-cancer
chemotherapeutic agents. It often involves overexpression of P-
glycoprotein, a plasma-membrane located protein of around 1280 amino
acids, composed of two duplicated halves, each of which contains six
predicted transmembrane helices and one nucleotide-binding site. There
is firm evidence that P-glycoprotein acts in an ATP-dependent manner to
exclude drugs and a wide variety of other hydrophobic compounds from
cells. We and others have established that P-glycoprotein displays
substantial drug-stimulated ATPase activity, and the most widely-
considered current hypothesis is that P-glycoprotein acts as an ATP-
driven drug-efflux pump.
We have recently generated a Chinese hamster ovary cell line that grows
vigorously and constitutively overexpress P-glycoprotein, up to 32%
(w/w) in isolated plasma membranes. Using this system as source
material, we propose to carry out a thorough biochemical investigation
of P-glycoprotein, involving purification to homogeneity, reconstitution
in liposomes, characterization of transport properties, detailed study
of the nucleotide binding sites and the catalysis of ATP hydrolysis, and
characterization of inhibitors of catalysis.
Basic knowledge of this kind will be invaluable in devising ways to
disable P-glycoprotein in cells and overcome multidrug-resistance in
patients.
多药耐药是中国癌症患者遇到的一种情况
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALAN E. SENIOR其他文献
ALAN E. SENIOR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALAN E. SENIOR', 18)}}的其他基金
FASEB SUMMER RESEARCH CONFERENCE: TRANSPORT ATPASES
FASEB 夏季研究会议:运输ATP酶
- 批准号:
7000990 - 财政年份:2005
- 资助金额:
$ 19.79万 - 项目类别:
相似海外基金
Tyrosine kinase inhibitor / 6-thiopurine drug interactions via nucleobase transporters
酪氨酸激酶抑制剂/6-硫嘌呤药物通过核碱基转运蛋白的相互作用
- 批准号:
540955-2019 - 财政年份:2019
- 资助金额:
$ 19.79万 - 项目类别:
University Undergraduate Student Research Awards














{{item.name}}会员




